This peer-reviewed publication highlights how amorphous solid dispersion dosage forms can improve patient compliance and efficacy of acalabrutinib and other weakly basic drugs that have pH-dependent absorption.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center